Cipla Launches Cipremi at $53.34 per Vial in India

 Cipla Launches Cipremi at $53.34 per Vial in India

Cipla Prices Ceprimi as Rs 4,000 per vial


  • Cipla has priced its generic version of remdesivir, Cipremi at Rs 4000 ($53.34/ 100ml) vial, making it the lowest priced COVID-19 therapy across the globe, when compared with Hetero’s Covifor which is sold at Rs 5,400/ 100 mg vial and Mylan’s Desrem is priced at Rs 4,800.
  • The company focuses on supplying over 80,000 vials within the first month. To ensure equitable distribution, Cipremi will be available via government and hospital channels 
  • On Jul 07, 2020, Sovereign Pharma, which is manufacturing and packaging the therapy for Cipla had dispatched the first batch. Gilead has priced the original version at $390/ 100 mg vial for developed countries while signed a license agreement with generic producers to make the treatment widely available

Click here to read full press release/ article | Ref: Reuters | Image: Express Pharma

Related News: Cipla Launches Cipremi (remdesivir lyophilized powder for injection 100 mg) to Treat Patients with Severe COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on

Related post